Abstract
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Grunfeld, C. et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 118, e20–e28 (2008).
Grunfeld, C. et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 24, 1717–1726 (2010).
Crane, H. M. et al. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med. 9, 780–786 (2008).
Koutkia, P. & Grinspoon, S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu. Rev. Med. 55, 303–317 (2004).
Rietschel, P. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metabol. 86, 504–510 (2001).
Lo, J. et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300, 509–519 (2008).
Stanley, T. L. et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab. 96, 150–158 (2011).
Koutkia, P. et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292, 210–218 (2004).
Ferdinandi, E. S. et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol. 100, 49–58 (2007).
US Food and Drug Administration. FDA labelling information — Egrifta (tesamorelin for injection) FDA website [online], (2010).
Falutz, J. et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359–2370 (2007).
Falutz, J. et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22, 1719–1728 (2008).
Falutz, J. et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metabol. 95, 4291–4304 (2010).
Després, J. P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9, 452–459 (1993).
Thörne, A. et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26, 193–199 (2002).
Klein, S. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549–2557 (2004).
Silverberg, M. J. et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Intern. Med. 150, 301–313 (2009).
Loe, D. Research Update (Versant Partners, 6 Dec 2010).
Maruoka, N. Daily Letter (Canaccord Genuity, 6 Dec 2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C.G. was an investigator in trials of growth hormone, tesamorelin and leptin; in that capacity he received research funding from and advised Theratechnologies, EMD Serono and Amgen.
Rights and permissions
About this article
Cite this article
Grunfeld, C., Dritselis, A. & Kirkpatrick, P. Tesamorelin. Nat Rev Drug Discov 10, 95–96 (2011). https://doi.org/10.1038/nrd3362
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3362
This article is cited by
-
Strategies to improve the physicochemical properties of peptide-based drugs
Pharmaceutical Research (2023)
-
Current understanding of the structure and function of family B GPCRs to design novel drugs
Hormones (2018)
-
Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy
Current Atherosclerosis Reports (2015)